Peter

Brian sold 2% of his Coinbase stake, about $110 million, to co-found a company called NewLimit in 2021. Its mission is to reprogram old human cells back to younger states. So when he tweets that aging is a “disease,” he’s not making a philosophical argument. He’s talking about a market he’s personally betting nine figures on. About 150,000 people die every day worldwide, and roughly two-thirds of those deaths are age-related. Heart disease, cancer, stroke, dementia, all conditions where age is the single biggest risk factor. NewLimit has raised about $250 million total. Kleiner Perkins led a $130 million round in May 2025. Then in October, Eli Lilly put in $45 million, pushing the valuation to $1.6 billion. What the company actually does: it uses AI models and lab experiments in a cycle to discover drugs that reprogram liver cells to behave like younger versions of themselves. Three prototype medicines so far. No human trials yet. Armstrong isn’t alone. Sam Altman put $180 million of his own money into Retro Biosciences, which is raising $1 billion at a $5 billion valuation with no clinical results to show yet. Jeff Bezos was among the early backers of Altos Labs, which launched with $3 billion in 2022. Add NewLimit’s $250 million and the total capital flowing into just these three longevity startups tops $4 billion. Longevity funding hit $8.5 billion across 331 deals in 2024, more than double the year before. By late 2025, half of all that money was going to cellular reprogramming (turning old cells young again), the same approach NewLimit and Retro both use. The catch: the FDA doesn’t classify aging as a disease. The WHO almost did but reversed course in 2022. So none of these companies can run trials targeting “aging” directly. They target Alzheimer’s, liver disease, immune decline, and hope the anti-aging effects follow. The track record so far is rough. AbbVie walked away from a $1.5 billion decade-long partnership with Google’s longevity arm Calico late last year. Unity Biotechnology once had a $700 million valuation, then dissolved entirely last year. When a CEO says aging “will be optional,” check where his money is. Armstrong’s is exactly where his tweet is.